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Abstract
Vitamin D and its main active metabolite 1,25-dihydroxyvitamin D serve a crucial role in maintenance of a healthy calcium 
metabolism, yet have additional roles in immune and central nervous system cell homeostasis. Serum levels of 25-hydroxyvi-
tamin D are a biomarker of future disease activity in patients with early relapsing–remitting multiple sclerosis (RRMS), and 
vitamin D supplementation in patients with low circulating 25-dihydroxyvitamin D levels has been anticipated as a potential 
efficacious treatment strategy. The results of the first large randomized clinical trials (RCTs), the SOLAR and CHOLINE 
studies, have now been published. The SOLAR study compared 14,000 IU of vitamin  D3 (cholecalciferol) per day with pla-
cebo for 48 weeks in 232 randomized patients, whereas CHOLINE compared vitamin  D3 100,000 IU every other week with 
placebo for 96 weeks in 129 randomized patients. All patients in both studies also used interferon-β-1a. None of the studies 
met their primary endpoints, which were no evidence of disease activity (NEDA-3) at 48 weeks in SOLAR and annualized 
relapse rate at 96 weeks in CHOLINE. Both studies did, however, suggest modest effects on secondary endpoints. Thus, 
vitamin D reduced the number of new or enlarging lesions and new T2 lesions in SOLAR, and the annualized relapse rate 
and number of new T1 lesions, volume of hypointense T1 lesions, and disability progression in the 90 patients who com-
pleted 96 weeks’ follow-up in CHOLINE. We conclude that none of the RCTs on vitamin supplementation in MS have met 
their primary clinical endpoint in the intention to treat cohorts. This contrasts the observation studies, where each 25 nmol/l 
increase in 25-hydroxyvitamin D levels were associated with 14–34% reducedrelapse risk and 15–50% reduced risk of new 
lesions on magnetic resonnance imaging. This discrepancy may have several explanations, including confounding and reverse 
causality in the observational studies. The power calculations of the RCTs have been based on the observational studies, 
and the RCTs may have been underpowered to detect less prominent yet important effects of vitamin D supplementation. 
Although the effect of vitamin D supplementation is uncertain and less pronounced than suggested by observational studies, 
current evidence still support that people with MS should avoid vitamin D insufficiency, and preferentially aim for vitamin 
D levels around 100 nmol/L or somewhat higher.
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Key Points 
A low vitamin D status predicts a higher risk of exac-
erbations and magnetic resonance imaging activity in 
people with early relapsing–remitting multiple sclerosis 
(RRMS).
Clinical trials on vitamin D supplementation in RRMS 
are negative on primary clinical endpoints.
The effect of vitamin D on multiple sclerosis activity is 
less pronounced than suggested by observational studies.
This discrepancy may reflect reverse causality or con-
founding in the observational studies, or differences in 
trial designs in terms of inclusion criteria, power for 
primary and secondary outcomes, disease-modifying 
therapy use, and duration and dose of vitamin D supple-
mentation in the clinical trials.
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1 Introduction
Vitamin D is the precursor of a potent steroid hormone with 
multiple biological effects including immunomodulation and 
neuroprotection [1, 2]. The history of vitamin D in multi-
ple sclerosis (MS) dates back to 1974, when Goldberg sug-
gested that inadequate intake of vitamin D, calcium, and 
magnesium in genetically predisposed individuals leads to 
abnormal lipid composition and unstable myelin, predispos-
ing to MS development later in adulthood [3]. Vitamin D 
receptors (VDRs) were discovered on human immune cells 
in 1983 [4], and immunomodulatory properties of vitamin 
D were reported in 1984 [5]. In 1986 the first clinical trial 
of vitamin D in MS reported that vitamin D supplementa-
tion reduced the relapse rate by 50% compared with pre-
treatment levels [6].
As for other conditions, the role of vitamin D supplemen-
tation in MS can only be determined in randomized clinical 
trials (RCTs) [7]. A Cochrane report concluded that very 
low-quality evidence suggests no benefit of vitamin D for 
patient-important outcomes [8]. Previously published RCTs 
have been underpowered with heterogeneous patient selec-
tions and are thus largely inconclusive. Very recently, the 
results of two larger RCTs on vitamin D as add on to inter-
feron (IFN)-β, SOLAR (Supplementation of  VigantOL®oil 
versus placebo as Add-on in patients with relapsing–remit-
ting multiple sclerosis receiving  Rebif® treatment) and 
CHOLINE  (Cholecalceferol in relapsing remitting MS: 
A randomized clinical trial), have been published [9, 10]. 
We review the role of vitamin D supplementation in MS in 
light of the results from RCTs, with particular focus on these 
recent advances.
2  Vitamin D Metabolism: Focus on Immune 
and Central Nervous System Cells
Vitamin D has a longstanding recognized vital role in main-
tenance of calcium homeostasis [11]. For its in vivo synthe-
sis, vitamin D requires exposure of the skin to ultraviolet 
(UV) B light to contribute to a metabolism pathway mostly 
mediated by cytochrome P450 superfamily enzymes. Vita-
min D comes in two isoforms: the plant-derived vitamin D2 
(ergocalciferol) and animal-derived vitamin D3 (cholecal-
ciferol). The most notable metabolites in this pathway are 
25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvita-
min D [1,25(OH)2D]. 25(OH)D is the most abundant vita-
min D metabolite in the circulation. Although the kidney is 
the main source of circulating 1,25(OH)2D, hydroxylation 
into this active metabolite can also occur in a multitude of 
MS-relevant cell types inside and outside the central nerv-
ous system (CNS), including T cells, B cells, monocytes, 
macrophages, dendritic cells, microglia, astrocytes, and neu-
rons [4, 12, 13] (reviewed by Smolders and colleagues [14, 
15]). Since all these cells also express the VDR in resting 
and/or activated states, both auto- and paracrine effects of 
this activated vitamin D can be anticipated. In the context 
of MS, this can occur both in the lymph nodes and also in 
the CNS itself. 25(OH)D is encountered in the cerebrospi-
nal fluid, as measured with mass spectrometry [16], and an 
upregulation of the enzymatic machinery to activate vita-
min D and VDRs have been found in active MS lesions [17]. 
In vitro and in animal models of MS, 1,25(OH)2D is mostly 
attributed anti-inflammatory properties in activated lympho-
cytes, myeloid cells, and glia [14, 15]. In neurons, homeo-
static functions have been observed. These observations 
make it tempting to interpret vitamin D as a promotor of a 
homeostatic state both in immune and CNS-resident cells.
3  Genetic and Epidemiological Evidence 
for Vitamin D as a Risk Factor for Multiple 
Sclerosis (MS) Development
In nested case–control studies, low circulating 25(OH)D lev-
els when compared with controls have been found in military 
personnel prior to MS onset [18], in blood spots taken with 
the heel prick in newborns who develop MS in later life [19], 
and even in mothers during pregnancy with a child develops 
MS in later life [20]. The causal interpretation of this asso-
ciation is challenging. Several lines of evidence support an 
effect of vitamin D on the onset of first symptoms of MS. 
A low vitamin D intake was found in participants of the 
Nurses Health Initiatives studies who developed MS in later 
life [21]. Furthermore, several vitamin D-associated single 
nucleotide genetic polymorphisms (SNPs) have been asso-
ciated with risk of MS in genome-wide association studies 
[22]. In Mendelian randomization studies a cumulative risk 
score of SNPs predicting low 25(OH)D levels was associ-
ated with MS, while an association of these SNPs by them-
selves with MS was lacking [23–25]. Although confounding 
from residual pleiotrophy, compensatory feedback interac-
tions, or other unknown factors cannot be totally excluded, 
these studies strongly support a causal role for vitamin D on 
MS development.
4  Experimental Animal Models: 
Inflammation and Beyond
The in vitro effect of various dosages of 1,25(OH)2D on neu-
ral stem cell proliferation and their differentiation to oligo-
dendrocytes has been studied [26]. Neural stem cells showed 
VDR expression, which was upregulated by 1,25(OH)2D, 
1189Vitamin D Supplementation in MS
leading to enhanced proliferation of neural stem cells and 
enhanced differentiation into neurons and oligodendrocytes.
4.1  Effects in the Experimental Autoimmune 
Encephalomyelitis Model
The activated form of vitamin  D3, 1,25(OH)2D3, is highly 
efficient in both disease prevention and treatment in experi-
mental autoimmune encephalomyelitis (EAE) mice [27, 28]. 
Most research has focused on the effect of vitamin D on lym-
phocyte activation (reviewed by Hayes et al. [29]). A recent 
study in a myelin oligodendrocyte glycoprotein (MOG) EAE 
model has investigated the effect of 1,25(OH)2D on oligo-
dendrocyte maturation and differentiation [30]. Intraperito-
neal injection of 1,25(OH)2D was associated with elevated 
numbers of neural stem cells, oligodendrocyte precursor 
cells, as well as oligodendrocytes in disease lesions in the 
CNS, suggesting also a potential for remyelination and neu-
ral repair in this animal model.
4.2  Effects in Toxic Models on Demyelination
The first study on the effect of vitamin D on remyelination 
was performed in the ethidium bromide (EB) model for 
demyelination [31], where direct injection of EB leads to oli-
godendroglial damage and subsequent demyelination [32]. 
Rats were given 5 µg/kg of vitamin D3 for 2, 7, or 28 days 
following local EB injection. Vitamin D3 administration 
reduced the EB-induced damage and increased the endog-
enous remyelination. In 2011, Wergeland and colleagues 
[33] performed a study on vitamin D using the cuprizone 
model, where mice are fed with cuprizone, leading to oligo-
dendrocyte death and a subsequent reversible demyelination 
[34]. The mice were given either a diet deficient of vitamin 
 D3 (< 50 IU/kg) or were supplemented with low (500 IU/
kg), high (6200 IU/kg), or very high (12,500 IU/kg) amounts 
of vitamin D3. High dosages of vitamin  D3 significantly 
reduced the extent of white matter demyelination. In a fol-
low-up study [35], mice receiving intraperitoneal injections 
of 1,25(OH)2D after induction of demyelination had signifi-
cantly faster remyelination than mice receiving placebo. In 
another study of remyelination, mice received cuprizone for 
5 weeks and were then either injected intraperitoneally with 
vitamin D diluted in olive oil or injected with olive oil only 
(SHAM) or were without any injection [36]. A significant 
increase in remyelination, as measured by MOG and CNPase 
(2′,3′-cyclic-nucleotide 3′-phosphodiesterase) expression, 
was seen in the vitamin D-injected group. Finally, high-dose 
vitamin D has been found to protect against axonal damage, 
as measured by loss of neurofilament-positive axons, in the 
cuprizone model if the vitamin D treatment started before 
induction of demyelination [37].
The mechanisms by which vitamin D can prevent demy-
elination and stimulate remyelination have been examined 
in some studies. Using proteomics, it was detected that 
125 proteins were differentially regulated in brains from 
1,25(OH)2D-treated mice during remyelination compared 
with placebo. The upregulated proteins were especially 
involved in calcium binding or in mitochondrial function 
[38]. Another study focused on the retinoid X  receptor 
(RXR)-γ, which has been shown to be a positive regulator 
of oligodendrocyte progenitor cell differentiation [39]. The 
authors demonstrated that RXR–VDR signaling induced 
oligodendrocyte precursor cell differentiation that was 
enhanced by vitamin D.
5  Low Vitamin D Status Predicts a More 
Active Disease Course in Early MS
Several, but not all, cohort studies have found that increas-
ing serum 25(OH)D levels are associated with low disease 
activity in clinically isolated syndrome (CIS) and relaps-
ing–remitting MS (RRMS). The risk of subsequent relapses 
was 14–34% lower for each 25 nmol/L (10 ng/L) increase in 
25(OH)D in subjects with CIS or RRMS (Table 1). This was 
particularly true for subjects with CIS [40, 41]. However, in 
other studies the effect was limited to subgroups with the 
youngest ages [42] or a specific genetic risk–allele constitu-
tion [43]. Notably, in the largest RRMS onset cohort studied, 
25(OH)D levels did not predict subsequent long-term relapse 
rate [44]. The predictive value of 25(OH)D levels for risk 
of Expanded Disability Severity Scale (EDSS) progression 
is even less certain. This association was found in a cohort 
of CIS patients [40], but not convincingly in cohorts with 
(advanced) RRMS or progressive MS [42–45].
Magnetic resonance imaging (MRI) is accepted as a more 
sensitive biomarker for inflammatory disease activity in MS 
than relapses. The risk of new/enlarging T2 and/or gado-
linium-enhancing T1 lesions on MRI decreased 15–50% 
for each 25 nmol/L increase in 25(OH)D levels in patients 
with CIS or RRMS (Table 2). This association appears more 
robust and reproducible when compared with relapse risk. It 
has been observed in cohorts of patients treated with IFN-β 
[40, 44]; however, in another study with repeated meas-
urements before and after initiation of IFN-β in the same 
patients, it was only observed prior to start, and not during 
the use of this drug [46]. Measures of total brain volume also 
showed a less marked reduction in CIS patients with higher 
25(OH)D levels [40], but not in RRMS [44]. Radiological 
and neurophysiological measures of remyelination have not 
been associated with 25(OH)D levels yet, albeit that retinal 
nerve fiber layer thinning as assessed with optical coherence 
tomography after recovery of optic neuritis (from any cause) 
was more pronounced in subjects with the lowest 25(OH)
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D levels [47]. Altogether, these findings suggest that low 
25(OH)D-levels early in disease characterize patients with 
a high risk of an active inflammatory disease course.
Several investigators explored correlations between 
25(OH)D levels and a wide variety of general immunologi-
cal outcomes in blood and cerebrospinal fluid of people with 
MS. The absence of a clear auto-antigen or single immuno-
logical biomarker that clearly defines the immune response 
in MS makes it difficult to fully appreciate the relevance of 
analytes tested. Additionally, small sample sizes give a high 
risk of bias, and the heterogeneity in assays used and sub-
jects included makes reproducibility an issue. Two studies 
Table 1  Association of 25-hydroxyvitamin D levels with relapse risk
25(OH)D 25-hydroxyvitamin D, ARR annualized relapse rate, CIS clinical isolated syndrome, HLA human leukocyte antigen, HR hazard ratio, 
IR incidence risk, NR not reported, RR relative risk, RRMS relapsing–remitting multiple sclerosis
a IR, RR, and HR for a relapse (yes/no) values were linearly recalculated to correspond with a 25 nmol/L (10 ng/L) increase of 25(OH)D levels, 
except for Runia et al. [87] and Kuhle et al. [41]
b For each doubling of 25(OH)D (non-linear relationship)
c Only quartiles reported (median level 49.3 nmol/L)
Study Year n Follow-up 
(years; median)
Proportional decrease in IR/RR/
HR for each 25 nmol/L increase 
in 25(OH)D (%)a
Specification
Simpson et al. [82] 2010 145 0.5 23 RRMS
Mowry et al. [86] 2010 110 1.7 34 Pediatric RRMS/CIS
Mowry et al. [43] 2012 469 5 14 Only HLA-DR15*01 single RRMS/
CIS, not in whole cohort
Runia et al. [87] 2012 73 1.7 27b RRMS
Ascherio et al. [40] 2014 465 5 26 CIS
Fitzgerald et al. [44] 2015 1482 2 NR RRMS, no effect ARR 
Kuhle et al. [41] 2015 1047 4.3 24c CIS, not in multivariate
Muris et al. [42] 2016 340 3 32 Only RRMS < 37.5 years, not in 
whole cohort
Table 2  Randomized clinical trials with clinical outcomes
CIS clinical isolated syndrome, D2 vitamin  D2, D3 vitamin  D3, EDSS Expanded Disability Severity Scale, GE gadolinium-enhancing T1 lesions, 
MRI magnetic resonance imaging, NEDA-3 no evidence on disease activity including relapses, EDSS, and MRI, RRMS relapsing–remitting mul-
tiple sclerosis
a Randomized/completed
b Secondary clinical outcomes in parentheses for studies with other primary outcomes
c 75,000 IU every 3 weeks plus 800 IU daily
Study, year Patients na Months Intervention Primary  outcomeb
Derakhshandi et al. [52], 2013 Optic neuritis 30/24 12 D3 50,000 IU weekly/placebo Conversion to RRMS negative
Salari et al. [53], 2015 Optic neuritis 74/52 5 D3 50,000 IU weekly/placebo Retinal nerve layer thickness negative
O’Connell et al. [54], 2017 CIS 32/29 5 D3 5000 IU/10,000 IU/placebo CD4 T cells negative (relapses/MRI 
negative)
Stein et al. [55], 2011 RRMS 23/20 6 High dose/D2 1000 IU GE/T2 lesions negative
Kampman et al. [56], 2012 RRMS 71/68 41 D3 20,000 IU weekly/placebo Relapses negative
Soilu-Hänninen et al. [62], 2012 RRMS 66/62 12 D3 20,000 IU weekly/placebo T2 lesion volume negative
Shaygannejad et al. [64], 2012 RRMS 50/50 12 Calcitriol 0–5 µg/placebo EDSS positive
Golan et al. [65], 2013 RRMS 45/30 12 4370 IUc/D3 800 IU Flu symptoms negative (relapses/EDSS 
negative)
Achiron et al. [66], 2015 RRMS 158/143 6 Alfacalcidiol 1 µg/placebo Fatigue positive (relapses positive)
Sotirchos et al. [67], 2016 RRMS 40/35 6 10,400/D3 800 IU CD4 T cells positive (relapses negative)
Hupperts et al. [9], 2019 RRMS 229/183 11 D3 14,000 IU/placebo NEDA-3 negative
Camu et al. [10], 2019 RRMS 129/90 21 D3 100,000 IU twice monthly/
placebo
Relapses negative
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are of note to discuss separately. First, a large dataset of 
participants in the BENEFIT (Betaferon/Betaseron in Newly 
Emerging multiple sclerosis For Initial Treatment) study was 
analyzed for interaction between 25(OH)D status, MRI dis-
ease activity, and whole-blood mRNA expression profiles 
[48]. A network shift comprising IFN responses and lymph 
node-homing molecules was observed in people with MS 
with higher 25(OH)D levels. A limitation of this study is 
that small yet significant effects of 25(OH)D on relevant sub-
fractions of cells may get lost in the whole-blood transcrip-
tome. Second, an inverse correlation was observed between 
25(OH)D levels and antibodies against the Epstein–Barr 
virus (EBV) nuclear antigen 1 (EBNA1) epitope in patients 
with MS [49]. A similar inverse correlation between 25(OH)
D levels and EBV viral load has been reported [50]. The 
strong association between EBV seropositivity and MS onset 
is well-known, and anti-EBNA1 IgG antibodies have been 
identified as predictors of MS risk and disease activity in 
several but not all studies [51].
6  Randomized Controlled Trials with Clinical 
Results
6.1  Clinical Trials in Optic Neuritis and Clinically 
Isolated Syndrome (CIS)
Intervention studies with clinical endpoints in CIS and MS 
are shown in Table 2.
Derakhshandi et al. [52] compared 50,000 IU of vitamin 
 D3 per week and placebo in patients with optic neuritis and 
serum vitamin D < 75 nmol/L. There were four dropouts in 
the placebo group and two in the vitamin D group, leaving 
only 11 and 13 patients, respectively, for the final analysis. 
End-of-study 25(OH)D levels were not reported. During the 
12-month follow-up, five patients in the placebo group and 
none in the vitamin D group experienced a second demyeli-
nating attack (p = 0.007). The authors also reported a signifi-
cant effect on several MRI outcomes (cortical, juxtacorti-
cal, corpus callosal, new gadolinium-enhancing, and new 
T2 lesions, and black holes). Distribution of baseline MRI 
characteristics was not reported.
In another study from Iran, Salari et al. [53] compared 
50,000 IU of vitamin D3 weekly with placebo in 74 patients 
with optic neuritis and baseline 25(OH)D < 60 nmol/L. A 
total of 52 patients completed the 24-week observation 
period. There was no effect of vitamin D treatment on retinal 
nerve fiber layer thickness, which was the primary endpoint. 
The effects on 25(OH)D levels and conversion to MS were 
not reported.
O’Connell et al. [54] compared 10,000 IU of vitamin 
 D3, 5000 IU of vitamin  D3, and placebo for 24 weeks in 
29 patients with CIS and 37 healthy controls. For the CIS 
patients, mean vitamin D levels were around 50 nmol/L at 
baseline and increased by 18 nmol/L in the placebo group, 
76 nmol/L in the vitamin D 5000 IU group, and 115 nmol/L 
in the vitamin D 10,000 IU group. There was no effect on 
the frequency of pro-inflammatory CD4 T cells, which was 
the primary endpoint. The only MS relapse during the study 
period occurred in the vitamin D 5000 IU arm. There was 
no effect on MRI outcomes (gadolinium-enhancing and new 
T2 lesions).
6.2  Clinical Trials in MS
In 2011, Stein and coworkers [55] performed a 6-month 
double-blind RCT of high-dose vitamin D2 6000 IU, versus 
1000 IU of vitamin  D2, with the aim of achieving serum 
25(OH)D 130–175 nmol/L in 23 RRMS patients, of whom 
19 were treated with IFN-β or glatiramer acetate [55]. 
Patients on immunomodulatory treatment had to have at 
least one relapse within the last 24 months. Brain MRI was 
performed at baseline and at months 4, 5, and 6, and primary 
endpoints were the cumulative number of new gadolinium-
enhancing lesions and change in the volume of T2 lesions. 
Median 25(OH)D increased from 54 to 69  nmol/L (Δ 
15 nmol/L) in the low-dose and from 59 to 120 nmol/L (Δ 
61 nmol/L) in the high-dose vitamin  D2 group. The primary 
outcome was negative, but after adjusting for entry EDSS, 
the exit EDSS was higher in the high-dose vitamin D group 
(p = 0.05), where four relapses were recorded versus two in 
the low-dose group (p = 0.04).
Kampman et al. [56] compared weekly supplementation 
with 20,000 IU of vitamin  D3 and placebo for 96 weeks in 68 
RRMS patients with EDSS ≤ 4.5 [56]. Approximately 50% 
of the patients received immunomodulatory drugs, mostly 
IFN-β. The trial was designed to study the effect on bone 
mass density, and no MRI outcomes were included. Neither 
bone mass density nor turnover were affected by vitamin D 
supplementation [57, 58]. The mean annualized relapse 
rate (ARR) at baseline was low (0.11 and 0.15 in the vita-
min D and placebo groups, respectively). Mean 25(OH)D 
levels increased from 55.6 to 123.1 nmol/L (Δ 67.5 nmol/L) 
in the vitamin D group and from 57.3 to 61.8 nmol/L (Δ 
4.5 nmol/L) in the placebo group. After 96 weeks, there 
was no significant difference in ARR (absolute difference 
0.10, 95% confidence interval [CI] − 0.07 to 0.27), EDSS 
(absolute difference − 0.01, 95% CI − 0.35 to 0.35), or MS 
functional composite components, grip strength, or fatigue. 
Secondary studies revealed no effect of vitamin D on inflam-
mation markers or neurofilament light chain in serum, except 
a non-significant reduction in neurofilament light chain lev-
els among patients not using conventional disease-modify-
ing treatment [59, 60]. Serum anti-EBNA1 antibody levels 
decreased significantly after 48 weeks’ supplementation, but 
not after 96 weeks [61].
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Soilu-Hänninen et al. [62] compared weekly supplemen-
tation with 20,000 IU vitamin D3 with placebo for 1 year. 
All 66 patients had RRMS and had used IFN-β for at least 
1 month prior to inclusion. As for the Kampman et al. [56] 
study, recent disease activity was not an inclusion criterion, 
but the ARR was higher (around 0.5 in both treatment arms). 
The primary endpoint was T2 burden. Mean serum 25(OH)
D changed from 54 nmol/L at baseline to 110 nmol/L at 
12 months in the vitamin D-treated group (Δ 56 nmol/L), 
and from 56 to 50 nmol/L in the placebo group. T2 lesion 
volume increased more in the placebo group (median change 
287 mm3) than in the vitamin D group (median change 
83 mm3). The vitamin D group also accumulated fewer new 
T2 lesions, but neither of these differences were statisti-
cally significant (p = 0.105 and 0.286, respectively). The 
ARR at study end was similar (0.26 and 0.28). The vitamin 
D group did, however, have significantly fewer T1 enhanc-
ing lesions (p = 0.004), as well as a tendency to reduced 
disability accumulation (p = 0.071) and improved timed 
tandem walk (p = 0.076). An array of soluble inflammatory 
mediators was analyzed, of which only the latency activated 
peptide of transforming growth factor (TGF)-β (47–55 pg/
mL; p = 0.0249) was reported as a single regulated molecule 
within the vitamin D arm [63].
Shaygannejad et al. [64] compared calcitriol in escalating 
doses up to 0.5 µg/day and placebo in 50 RRMS patients. 
Recent disease activity was not an inclusion criterion. The 
patients had to be clinically stable during the last month 
before study entry, and to have 25(OH)D > 100 nmol/L 
at baseline. Further information about 25(OH)D levels 
throughout the study was not reported. ARR decreased sig-
nificantly in both groups, and was 1.04 at baseline and 0.32 
at study end in the vitamin D group and 1.04 and 0.40 in the 
placebo group. EDSS remained stable (1.6) in the vitamin D 
group and increased from 1.70 to 1.94 in the placebo group. 
When comparing between groups, only the difference in 
EDSS change was significant (p < 0.05).
In 2013, Golan et al. [65] performed a 1-year double-
blind RCT of daily supplementation with 4370 versus 
800 IU of vitamin  D3 in 45 patients on IFN-β, with reduction 
in flu-like symptoms as the primary endpoint. Mean serum 
25(OH)D increased from 48 to 68 nmol/L (Δ 20 nmol/L) 
and from 48.2 to 122.6 nmol/L (Δ 74.4 nmol/L) in the low- 
and high-dose groups, respectively. The primary endpoint 
was negative, and there was no difference in ARR at the 
end of the study (mean ± standard deviation 0.34 ± 0.27 vs. 
0.51 ± 0.34 in the low- and high-dose groups, respectively). 
One patient in the high-dose group with ARR 0 at baseline 
had three relapses during the study. Circulating interleukin 
(IL)-17 increased in the placebo (p = 0.037) but not the vita-
min D3 group.
Achiron et al. [66] compared the effect of 1 µg/day of the 
vitamin D3 metabolite alfacalcidol for 6 months in 158 MS 
patients with significant fatigue [66]. The majority of the 
patients had RRMS, with mean ± standard deviation disease 
duration 6.2 ± 5.5 years and EDSS score 2.9 ± 2.6. The effect 
on 25(OH)D levels was not reported. Alfacalcidol decreased 
the mean relative fatigue severity impact score, which was 
the primary endpoint, as compared with placebo (− 41.6% 
vs. − 27.4%; p = 0.007). There was also an effect on relapses, 
with eight relapses in the alfacalcidol-treated arm compared 
with 25 in the placebo arm (p = 0.006), but not on EDSS.
Sotirchos et al. [67] compared 10,400 and 800 IU of vita-
min  D3 daily for 6 months in 40 RRMS patients. Changes in 
the proportion of IFN-γ+ and IL-17+CD4+ T cells were the 
primary endpoints [67]. The majority of the patients were 
treated with either IFN-β, glatiramer acetate, natalizumab, or 
fingolimod. Mean 25(OH)D levels at baseline were 67.6 and 
69.3 nmol/L in the low- and high-dose groups, and increased 
by 17.0 and 86.2 nmol/L, respectively. There was a reduc-
tion in the proportion of IL-17+CD4+ T cells,  CD161+CD4+ 
T cells, and effector memory  CD4+ T cells in the high-dose 
vitamin D group only. Relapses were the only clinical out-
come reported, with one in each study arm.
SOLAR was a randomized, double-blind, multicenter 
study comparing vitamin  D3 (6670  IU increasing to 
14,000 IU per day after 4 weeks) with placebo for 48 weeks, 
including 232 RRMS patients aged 18–55 years from Den-
mark, Estonia, Finland, Germany, Italy, Latvia, Lithuania, 
The Netherlands, Norway, Portugal, and Switzerland [9]. 
Three patients did not receive study medication, leaving 229 
patients for the intention-to-treat (ITT) analyses. Inclusion 
criteria were first clinical event occurring within 5 years, 
EDSS score ≤ 4.0, relapse or gadolinium-enhancing MRI 
lesion within the last 18 months, no or low vitamin D sup-
plementation, and treatment with IFN-β-1a 44 µg three times 
weekly for 3–18 months. Median 25(OH)D levels at baseline 
and week 48 were 53 and 215 nmol/L (Δ 162 nmol/L) in 
the vitamin D group, and 54 and 49 nmol/L (Δ − 5 nmol/L) 
in the placebo group. Due to slow inclusion, the primary 
endpoint was changed during the study from new T2 lesions 
at week 48 and the proportion of relapse-free patients at 
week 96 [68] to no evidence of disease activity (NEDA-
3), defined as no relapses, EDSS progression, or combined 
unique MRI activity (CUA; new gadolinium-enhancing or 
new/enlarging T2 lesions) at week 48. Overall, 36.3% of 
patients in the vitamin D group and 35.3% in the placebo 
group had NEDA-3 at 48 weeks (p = 0.80). For the second-
ary endpoints, vitamin D supplementation was associated 
with a 32% reduction in the number of CUA lesions com-
pared with placebo (p = 0.0045) and change from baseline 
in total volume of T2 lesions at week 48 (3.57% vs. 6.07%; 
p = 0.035). The vitamin D group also tended to have a 
lower ARR (30%; p = 0.17) and risk of EDSS progression 
(odds ratio [OR] 0.77; p = 0.39). The proportion of relapse-
free patients at week 48 was similar and there were no 
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statistically significant differences between vitamin D3 and 
placebo for time to confirmed EDSS progression at week 48. 
No safety issues appeared.
A subgroup of 53 Dutch participants in SOLAR was ana-
lyzed in a substudy, SOLARIUM (SOLAR ImmUne Modu-
lating effects). In the treatment arm of this subgroup, 25(OH)
D levels increased from 60 to 231 nmol/L (Δ 171 nmol/L) 
and remained stable in the placebo group (54 and 60 nmol/L, 
respectively [Δ 6 nmol/L]). On the whole, there were no dif-
ferences between treatment arms regarding proportions of 
regulatory T and B cell subsets or T cell cytokine profiles 
[69, 70]. A within-treatment arm 48-week reduction of IL-
4-positive T cells (mean 3.7–2.9%; p = 0.04), a reduction of 
CD25 protein expression by regulatory T cells, and a reduc-
tion in soluble CD25 was observed in the placebo group but 
not in the vitamin D-supplemented group [69, 71]. Defini-
tive interpretation of these data requires further study. In the 
vitamin D group, there was a reduction of anti-EBNA1 IgG 
levels (median 526–455; p < 0.001), which was not seen in 
the placebo-group [72].
CHOLINE was a multicenter, double-blind, placebo-
controlled, parallel-group randomized controlled trial in 
RRMS patients across 27 centers in France comparing 
vitamin  D3 (100,000 IU every other week) to placebo for 
96 weeks [10]. A total of 181 patients were recruited, of 
whom 129 were randomly assigned to receive vitamin  D3 
(n = 63) or placebo (n = 66). Inclusion criteria were age 
18–65 years, EDSS score from 0 to 5, at least one docu-
mented relapse during the previous 2 years, stable disease 
(no episode in the 30 days before screening), serum 25(OH)
D concentration < 75 nmol/L, and treatment with subcuta-
neous IFN-β-1a 44 µg three times weekly for 4 ± 2 months. 
The primary endpoint was ARR at 96 weeks. Change in 
time of MRI parameters, EDSS, 3-level version of EQ-5D 
(EQ-5D-3L), Paced Auditory Serial Addition Task 3, sec-
ond version (PASAT-3) scores, and safety were the sec-
ondary endpoints. Mean serum 25(OH)D levels in the 
vitamin  D3 group raised from 49.19 nmol/L at baseline 
to 156.92 nmol/L at 2 years (Δ 107.73 nmol/L). ARR was 
reduced by the vitamin  D3 treatment but the difference was 
statistically non-significant in the ITT sample (rate ratio 
[rR] = 0.799, 95% CI 0.481–1.32; p = 0.379), as well as 
on a per protocol basis (rR = 0.630, 95% CI 0.353–1.101; 
p = 0.111). Safety was good. A total of 39 patients could not 
reach the 2-year follow-up; thus, the completers’ population 
was composed of 90 subjects (45 vitamin  D3 and 45 pla-
cebo). In those patients, treatment with vitamin  D3 was asso-
ciated with a lower ARR (rR = 0.403, 95% CI 0.208–0.814; 
p = 0.012), a reduction in the number of new T1-weighted 
lesions (rR = 0.494, 95% CI 0.267–0.913; p = 0.025), a lower 
volume of hypointense T1-weighted MRI lesions (− 312, 
95% CI − 596 to − 29; p = 0.031), and a lower progression 
of EDSS (− 0.06 ± 0.78 vs. 0.32 ± 0.87, 95% CI − 0.614 to 
− 0.043; p = 0.026).
7  Safety
No RCTs revealed significant adverse events that can be 
attributed to even highly dosed vitamin D supplements in 
addition to other disease-modifying therapies (DMTs) [9, 
10, 56, 62, 67]. Various notes of caution have been published 
regarding hypercalcemia as the main manifestation of vita-
min D toxicity [11]. In one study, mice with EAE developed 
hypercalcemia after being supplemented with high doses of 
vitamin D [73]. Hypercalcemia was not seen in the human 
RCTs in MS, but has been described in an MS patient tak-
ing high doses of both vitamin D3 and calcium supplements 
[74]. An additional case report suggests relevant toxic effects 
of ultra-high doses of vitamin D exceeding 50,000 IU/day 
[75], but the added value of reaching these high 25(OH)
D levels can be debated based on the spectrum of RCTs 
performed (see Sect. 6.2). There are no safety concerns for 
vitamin  D3 supplements when targeting the (high) physi-
ological range.
8  Interpretation of Randomized Controlled 
Trial Data
When assessing the studies performed thus far, a discrep-
ancy between observational studies and trials becomes emi-
nent. In the observation studies, each 25 nmol/L increase in 
25(OH)D was associated with a 14–34% reduced relapse 
risk and 15–50% reduced risk of new MRI lesions (Tables 2 
and 3). Average baseline 25(OH)D levels of 53 nmol/L were 
elevated with approximately 108 nmol/L in the supplementa-
tion studies (Fig. 1). If the reported associations in the obser-
vational studies could be directly extrapolated, this would 
imply a huge treatment effect of vitamin D, with an almost 
abrogation of disease activity. Clearly, this is not what has 
been observed. Although the MRI data from the new RCTs 
suggest that there is a beneficial effect of vitamin D [9, 10], 
no single study met its primary endpoint in the ITT cohorts. 
What happened?
A first explanation is that associations between vitamin D 
status and MS outcomes are likely not entirely driven by 
a direct effect of vitamin D on the disease course of MS. 
There is a substantial body of evidence that 1,25(OH)2D is 
an anti-inflammatory molecule, and Mendelic randomization 
studies strongly support a qualitative effect of vitamin D on 
MS onset (see Sect. 3). However, these studies do not clarify 
the quantitative contribution of this effect to the associa-
tions observed. Reverse causality may operate at the same 
time (Fig. 2). Since inflammation lowers 25(OH)D levels 
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[76], an active immune system more prone to accumulate 
in MS or subclinical disease activity may reduce 25(OH)
D levels. Additionally, subclinical disease activity and dis-
ability may induce sun-avoiding behavior [77]. Furthermore, 
association studies can be confounded by other factors that 
elevate 25(OH)D and suppress MS activity, without the lat-
ter two being related. UVB exposure has direct immune-
modulating effects, and low UVB/sun exposure has indeed 
been shown to be an independent risk factor for MS devel-
opment and early progression [78]. UVB exposure is thus 
likely the main confounding factor for vitamin D in MS, and 
UVB phototherapy is currently also under investigation for 
disease-modifying properties in MS [79]. A higher body 
mass index (BMI) is associated with lower 25(OH)D levels 
but also with brain atrophy and a more detrimental disease 
course in MS [80, 81]. Furthermore, unknown factors in diet 
and general physical activity may affect desease course and 
also be associated with 25(OH)D levels.
Second, since most RCTs on vitamin D have been pow-
ered based on results from observational studies, they are 
much smaller than studies on conventional immunomodula-
tory drugs and may lack the power to detect smaller effects 
of vitamin D supplements. Signals supporting this hypoth-
esis come from secondary endpoints, where improved MRI 
Table 3  Association of 25-hydroxyvitamin D levels with occurrence of magnetic resonance imaging lesions
25(OH)D 25-hydroxyvitamin D, CIS clinically isolated syndrome, GE new gadolinium-enhancing T1 lesions, HR hazard ratio, IR incidence risk, 
MRI magnetic resonance imaging, OR odds ratio, RR relative risk, RRMS relapsing–remitting multiple sclerosis, T2 new T2 lesions
a OR, IR, RR, and HR for a new MRI lesion (yes/no) values were linearly recalculated to correspond with a 25 nmol/L (10 ng/L) increase in 
25(OH)D levels
b No effect of 25(OH) D during 1.5 subsequent years on interferon-β
Study Year n Follow-up 
(years)
Proportional decrease in OR/IR/RR/HR for 
each 25 nmol/L increase in 25(OH)D (%)a
Specification
Mowry et al. [43] 2012 469 5 15 T2, RRMS/CIS
32 GE, RRMS/CIS
Løken-Amsrud et al. [46] 2012 88 0.5 29 T2, untreated  RRMSb
32 GE, untreated  RRMSb
Ascherio et al. [40] 2014 465 5 29–32 T2/GE, CIS
Fitzgerald et al. [44] 2015 1482 2 16 T2/GE, RRMS
Cree et al. [45] 2016 517 2 50 GE, only in RRMS subgroup








































Fig. 1  Reported median/mean baseline 25-hydroxyvitamin  D 
[25(OH)D] levels and the reported mean/median elevation of 25(OH)
D levels in the supplementation arms of controlled vitamin  D2/D3 
supplementation studies. Studies are labeled with the first author 
names of the study reports [9, 10, 54–56, 62, 65, 67]. Dot size cor-
responds with sample size of the intention-to-treat cohorts (smallest 
n < 25, largest n > 200)
Fig. 2  Interaction of vitamin  D status with multiple sclerosis (MS) 
onset and MS disease activity. When an effect of vitamin D on 
the disease course of MS is assumed, the association may also be 
explained by an effect of these MS outcomes on vitamin D (reverse 
causality) or by an effect of another factor that suppresses MS and 
promotes vitamin D (confounding). Reprinted from Smolders et  al. 
[97], with permission from Elsevier. 25(OH)D 25-hydroxyvitamin D, 
EDSS Expanded Disability Severity Scale, MRI magnetic resonance 
imaging
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endpoints are reported in vitamin D arms [9, 62], or in 
subgroups of protocol completers [10]. These small sample 
sizes do not allow post hoc analyses of subgroups which may 
have had the most benefit of supplements, as has been sug-
gested in the observational studies (Tables 1 and 2). A meta-
analysis with sensitivity analyses could suggest whether 
patients with the lowest 25(OH)D levels, the shortest disease 
duration (i.e., CIS vs. advanced RRMS), or the most active 
disease course of MS have more prominent treatment effects. 
The last subgroup may be suggested by the absence of sig-
nificant effects of vitamin D supplements on dichotomized 
outcomes (i.e., relapse free and free from active lesions as 
included in NEDA-3) versus continuous outcomes (relapse 
rate and number of active lesions) in SOLAR [9]. The 
same could hypothetically account for participants with the 
highest anti-EBNA1 IgG levels, the only biomarker that is 
reduced after vitamin  D3 supplements in independent RRMS 
cohorts [61, 72]. It should also be pointed out that the dura-
tion of the RCTs is 2 years or shorter, while observation 
studies have shown positive effects on disease course during 
a much longer follow-up [40]. This is, however, not likely 
to fully explain the discrepancies between the results from 
RCTs and observational studies, as several observational 
studies showed short-term results [43–45, 54]. Lastly, most 
large RCTs have so far either exclusively or predominantly 
included patients on IFN-β [9, 10, 56, 62, 65]. It is possible 
that the effect of vitamin D would be different in combina-
tion with another disease-modifying drug. However, it is not 
plausible that this will apply for drugs that reduce inflamma-
tory disease activity more efficiently than IFN-β. Addition-
ally, the largest observational studies showing associations 
between 25(OH)D levels and disease activity in MS also 
included predominantly IFN-β-treated participants [38, 42, 
82, 83].
The studies performed thus far were helpful to downscale 
the enormous expectations of vitamin D supplements as a 
disease-modifying treatment in MS, and to provide at least 
some hopeful signals that a treatment effect may be pre-
sent on selected outcomes in selected subgroups. However, 
no single RCT thus far was of sufficient size to pinpoint 
these subgroups. Currently, the most urgent need is a sup-
plementation study that reaches its primary endpoint and 
confirms the main assumptions of its design. Until then, the 
relevance of vitamin D supplements for the management of 
active RRMS will remain a matter of debate.
In addition to the question of efficacy, there are other 
knowledge gaps to bridge. One main question is how much 
vitamin D should be supplemented, and which 25(OH)D lev-
els should be targeted. Three observations are worthwhile to 
take into account when thinking about this issue. First, sub-
jects with 25(OH)D levels exceeding 100 nmol/L did best 
on the outcomes investigated in the MS incidence studies, 
as was recently propagated by the European Committee for 
Treatment and Research in Multiple Sclerosis (ECTRIMS) 
environmental risk factor workshop [84]. Second, an 
inverse association between relapse risk and 25(OH)D lev-
els reached could only be observed for 25(OH)D levels up 
to 110 nmol/L in an uncontrolled study—above this, the 
association was lost [85]. Observational studies generally 
also did not include subjects with 25(OH)D levels exceed-
ing 150 nmol/L [43, 46, 82, 86, 87]. Third, the largest vita-
min D3 supplementation studies performed thus far did not 
show any convincing signals supporting a relevant benefit of 
targeting supraphysiological 25(OH)D levels [9] versus the 
(high) physiological range [62, 88]. Optimally, this observa-
tion should be subject to meta-analysis of RCT data. Based 
on these observations, targeting levels of 100 nmol/L would 
be a reasonable strategy, and no observations support higher 
levels [73].
9  Why and How to Pursue a Role of Vitamin 
D as a Disease‑Modifying Therapy in MS?
A legitimate question that arises is whether it is worthwhile 
to pursue the research on potential benefits of vitamin D 
supplementation for people with MS. As elaborated in this 
review, treatment effects are likely small when compared 
to the expanding package of highly efficacious DMTs [74]. 
Efficacy can be weighed against various variables, includ-
ing the efficacy of other DMTs. An alternative approach 
is to weigh efficacy against potential harmful effects of a 
treatment. Although not elaborated on, no RCTs revealed 
adverse events that can be attributed to vitamin D supple-
ments. Efficacy can also be weighed against economic costs. 
Vitamin  D3 supplements, even in high doses, are very inex-
pensive when compared to DMTs. Should the point estimate 
for ARR reduction as reported in the SOLAR trial hold true 
in future powered studies [9], the crude compound costs 
to achieve this reduction could be much lower than that of 
licensed first-line disease-modifying drugs, although these 
have larger effect sizes [75]. A favorable cost–benefit ratio 
regarding burden for patients in terms of adverse effects and 
for society in terms of financial costs could justify a less 
impressive efficacy. However, it should be underscored that 
the beneficial effect of vitamin D in MS remains unproven, 
and thus does not fulfill the criteria for reimbursement by 
public healthcare systems.
Luckily, several RCTs are still ongoing, and these will 
provide additional information on vitamin  D3 supplementa-
tion in MS (summarized in Amato et al. [84]). However, 
it remains unlikely that these (small) studies will be able 
to completely bridge the aforementioned knowledge gaps 
regarding dosing, subgroups, 25(OH)D levels, and dis-
ease activity. These issues call for meta-analyses of origi-
nal study data and, optimally, large-scale clinical trials of 
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sufficient power to allow subgroup analyses. We propose 
that such a trial should include RRMS patients early in their 
disease, with clinical or MRI activity, and that 25(OH)D 
levels exceeding 100 nmol/L should be targeted in addition 
to conventional DMTs. Inclusion of patients with the low-
est 25(OH)D levels will likely increase the odds of a trial 
achieving positive results on its primary endpoint. Although 
the evidence for low 25(OH)D levels as a biomarker for 
active MS is mounting, the current absence of significant 
effects on primary efficacy endpoints makes it ethically 
sound to compare vitamin D supplementation with placebo 
in such a trial [89].
In addition to established clinical and MRI endpoints, 
measuring biomarkers of end-organ damage in samples col-
lected from the ongoing or already conducted studies would 
be of added value. Neurofilament light chain has been shown 
to reflect therapeutic effects in MS, and the serum concentra-
tion is tightly correlated with that in cerebrospinal fluid [81]. 
Vitamin D supplementation had no overall effect on neuro-
filament light chain in the only study published so far [60]. 
However, the baseline inflammatory activity in this study 
was low, and in spite of that there was a positive trend in the 
subgroup not treated with conventional disease-modifying 
drugs. Hopefully other studies can extend these data.
10  Advice for People with MS and Clinicians 
Based on Current Data
Low serum levels of 25(OH)D are frequently encountered 
in people with MS [83], and are useful for patients and cli-
nicians to unveil. First, even at the start of their disease, 
people with MS report an increased tendency to fall and have 
more fractures than people without MS [90–92]. Low bone 
mineral density is frequent already at the time of diagnosis 
[93]. Although high-dose supplementation did not prevent 
bone loss in a cohort with relatively good vitamin D status 
[57, 58], correction of the lowest 25(OH)D levels may pro-
mote bone health and reduce fracture risk [11]. The optimal 
25(OH)D level for bone health is not established, but it is 
generally accepted that vitamin D levels < 50 nmol/L are 
suboptimal [94]. When assessing vitamin D measurements 
in individual patients, seasonal variation should be taken 
into account. The serum level in Scandinavian MS patients 
is likely to be 50% lower in late winter/spring than in late 
summer [95], but this is probably different in other geo-
graphical areas where seasonal variations in UV exposure 
and sun habits are different. Second, since low 25(OH)D 
levels are a biomarker of higher subsequent disease activity 
(see Sect. 8), it could be used in prognostic considerations 
and treatment decisions in early MS. Third, although not 
conclusive, we presented reasonable data from observa-
tional studies and RCTs which suggest a benefit for patients 
who elevate their 25(OH)D to higher levels (see Sect. 8). 
This fits in the current concept of promoting general brain 
health [94], in which a healthy diet, active lifestyle, not being 
obese, and cessation of smoking and alcohol are promoted 
to make the CNS more resilient to the inflammatory attack 
of MS. Prevention of the lowest 25(OH)D ranges, associ-
ated with loss of bone mineral density and the most detri-
mental endpoints in MS, can be achieved with vitamin  D3 
1000–2000 IU/day. The earlier suggested optimal 25(OH)D 
levels exceeding 100 nmol/L [73, 84] were achieved in the 
context of a controlled study by supplementing people with 
RRMS with vitamin  D3 4000 IU/day [96]. This would be 
reasonable advice for people with MS in northern parts of 
Europe and North America, whereas people in Australia and 
other more sunny areas may require less supplementation.
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